目的 通過建立信迪利單抗注射液合理應(yīng)用評(píng)價(jià)標(biāo)準(zhǔn),分析臨床用藥情況,為合理用藥提供參考。方法 參考藥品說明書與循證依據(jù)制定信迪利單抗注射液臨床合理應(yīng)用評(píng)價(jià)標(biāo)準(zhǔn)。應(yīng)用該標(biāo)準(zhǔn)對(duì)蕪湖市第二人民醫(yī)院2021年1月至10月使用信迪利單抗注射液患者的病例資料與用藥醫(yī)囑進(jìn)行合理性評(píng)價(jià)。結(jié)果 信迪利單抗注射液臨床不合理類型主要包括適應(yīng)證不合理35例(33.98%),特殊要求不符合8例(7.77%)以及用法用量不合理6例(5.83%)。103份病例中,符合說明書適應(yīng)證1例,超說明書適應(yīng)證102例(99.03%)。結(jié)論 蕪湖市第二人民醫(yī)院建立的信迪利單抗注射液合理使用評(píng)價(jià)標(biāo)準(zhǔn)有實(shí)際應(yīng)用價(jià)值,可為同類藥物合理使用提供參考。

Objective To analyze the clinical drug use by establishing the evaluation criteria for rational use of Sintilimab Injection, and to provide reference for rational drug use. Methods The clinical rational application evaluation standard of Sintilimab Injection was formulated with reference to the drug insert and evidence-based basis. This standard was used to evaluate the rationality of the case data and medication orders of patients using Sintilimab Injection in the Second People's Hospital of Wuhu from January to October 2021. Results The clinical unreasonable types of Sintilimab Injection mainly included 35 cases (33.98%) with unreasonable indications, unsuitable special requirements 8 cases (7.77%) and unreasonable usage and dosage 6 cases (5.83%). Among the 103 cases, 1 case met the indications on the label, and 102 cases (99.03%) had off-label indications. Conclusion The evaluation standard for rational use of sintilimab injection established by our hospital has practical application value and can provide a reference for the rational use of similar drugs.

R979.1